Slingshot Insights | Bbio Overview

BBIO Overview

Upcoming Projects (BBIO)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (BBIO)

A second look: Revisiting the HELIOS-B data for vutrisiran in ATTR-CM following publication in NEJM and presentation at ESC
Tickers: ALNY, BBIO, PFE
Executed On: Oct 22, 2024 at 03:00 PM EDT
A third look: Revisiting the HELIOS-B data for vutrisiran in ATTR-CM following publication in NEJM and presentation at ESC
Tickers: ALNY, BBIO, PFE
Executed On: Oct 15, 2024 at 05:00 PM EDT
Revisiting the HELIOS-B data for vutrisiran in ATTR-CM following publication in NEJM and presentation at ESC
Tickers: ALNY, BBIO, PFE
Executed On: Sep 12, 2024 at 12:30 PM EDT
A Second View: Examining the results of the Phase 3 ATTRibute-CM study of acoramidis in ATTR-CM by BridgeBio Pharma presented at International Symposium of Amyloidosis (ISA)
Ticker: BBIO
Executed On: Jun 24, 2024 at 11:00 AM EDT
Examining the results of the Phase 3 ATTRibute-CM study of acoramidis in ATTR-CM by BridgeBio Pharma presented at International Symposium of Amyloidosis (ISA)
Ticker: BBIO
Executed On: Jun 13, 2024 at 11:30 AM EDT
A Second View: Diving into the EDIT-301 ASH Clinical Data Abstract and the approval of CASGEVY & Lyfgenia
Tickers: EDIT, BLUE, CRSP, VRTX, BBIO
Executed On: Dec 21, 2023 at 12:00 PM EST
Diving into the EDIT-301 ASH Clinical Data Abstract and the approval of CASGEVY & Lyfgenia
Tickers: EDIT, BLUE, CRSP, VRTX, BBIO
Executed On: Dec 20, 2023 at 05:00 PM EST
A Third View: Taking a look at the ongoing NTLA's study of NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy and BBIO's phase 3 attribute-cm study of acoramidis in patients with transthyretin (ATTR) amyloidosis
Tickers: NTLA, BBIO
Executed On: Nov 28, 2023 at 04:00 PM EST
A Second View: Taking a look at the ongoing NTLA's study of NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy and BBIO's phase 3 attribute-cm study of acoramidis in patients with transthyretin (ATTR) amyloidosis
Tickers: NTLA, BBIO
Executed On: Nov 16, 2023 at 10:00 AM EST
Taking a look at the ongoing NTLA's study of NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy and BBIO's phase 3 attribute-cm study of acoramidis in patients with transthyretin (ATTR) amyloidosis
Tickers: NTLA, BBIO
Executed On: Nov 15, 2023 at 12:00 PM EST
A Second Opinion: An updated look at the potential of Acoramidis following Part B results of the Attribute-CM trial
Tickers: BBIO, PFE
Executed On: Sep 21, 2023 at 12:00 PM EDT
An updated look at the potential of Acoramidis following Part B results of the Attribute-CM trial
Tickers: BBIO, PFE
Executed On: Sep 01, 2023 at 09:30 AM EDT
A Second Opinion: Discussing Acoramidis following Part B results of the Attribute-CM trial
Tickers: BBIO, PFE
Executed On: Jul 27, 2023 at 01:00 PM EDT
Discussing Acoramidis following Part B results of the Attribute-CM trial
Tickers: BBIO, PFE
Executed On: Jul 19, 2023 at 04:30 PM EDT
Discussing the potential of BBP-398, an SHP2 inhibitor with indications for NSCLC and advanced solid tumor
Ticker: BBIO
Executed On: Jul 22, 2022 at 12:00 PM EDT
A look at Acoramidis following failure of Part A of Attribute-CM trial
Tickers: BBIO, PFE
Executed On: Jan 18, 2022 at 12:00 PM EST

Upcoming & Overdue Catalysts (BBIO)

Don’t see a catalyst related to the company you care about? Create your own!

Strategic Initiatives (BBIO)

Don’t see a strategic initiative related to the company you care about? Create your own!